Xinbin Gu
Overview
Explore the profile of Xinbin Gu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
459
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
12.
Wan S, Cao S, Wang X, Zhou Y, Yan W, Gu X, et al.
Vaccines (Basel)
. 2021 Apr;
9(4).
PMID: 33916109
The flavivirus Zika (ZIKV) has emerged as a global threat, making the development of a ZIKV vaccine a priority. While live-attenuated vaccines are known to induce long-term immunity but reduced...
13.
Xie G, Zhu A, Gu X
Head Neck
. 2021 Feb;
43(6):1721-1729.
PMID: 33533173
Background: Epidermal growth factor receptor (EGFR) overexpression is one of the most notable characteristics in head and neck squamous cell carcinoma (HNSCC). The MAPK kinase (MEK) inhibitor trametinib has shown...
14.
Lin X, Sajith A, Wang S, Kumari N, Choy M, Ahmad A, et al.
ACS Infect Dis
. 2020 Dec;
6(12):3190-3211.
PMID: 33258581
Combination antiretroviral therapy (cART) suppresses human immunodeficiency virus-1 (HIV-1) replication but is unable to permanently eradicate HIV-1. Importantly, cART does not target HIV-1 transcription, which is reactivated in latently infected...
15.
Wan S, Cao S, Wang X, Zhou Y, Yan W, Gu X, et al.
Virology
. 2020 Oct;
552:73-82.
PMID: 33075709
Zika virus (ZIKV) is a mosquito-borne flavivirus that replicates in both vertebrate and insect cells, whereas insect-specific flaviviruses (ISF) replicate only in insect cells. We sought to convert ZIKV, from...
16.
Zhou X, Zhu A, Gu X, Xie G
Cell Oncol (Dordr)
. 2019 Feb;
42(3):369-380.
PMID: 30788663
Background: Hepatocellular carcinoma (HCC) is an aggressive malignancy. In HCC, mitogen-activated protein kinase (MAPK) signaling is overactivated. The MAPK kinase (MEK) inhibitor trametinib has been approved to treat several types...
17.
Sha W, Zhou Y, Ling Z, Xie G, Pang X, Wang P, et al.
Oncotarget
. 2018 Dec;
9(91):36331-36343.
PMID: 30555632
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options. It is urgent to develop new therapeutics against this disease. Salvinolic acid B (Sal-B) is...
18.
Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges
Zhu S, Liu Y, Wang P, Gu X, Shan L
Biomed Res Int
. 2017 Jul;
2017:7929286.
PMID: 28752098
Recombinant immunotoxins (RITs) refer to a group of recombinant protein-based therapeutics, which consists of two components: an antibody variable fragment or a specific ligand that allows RITs to bind specifically...
19.
Wu X, Zhu A, Pang X, Xie G, Gu X
Anal Biochem
. 2017 Mar;
526:50-57.
PMID: 28322802
We describe a simple method to accurately detect and quantify both Pten mutation and allele-specific loss using allele-specific PCR analysis. Our approach used a heterozygous genomic DNA with one wild-type...
20.
Zhao Y, Ling Z, Hao Y, Pang X, Han X, Califano J, et al.
Oncotarget
. 2017 Feb;
8(15):25005-25020.
PMID: 28212569
By analyzing the expression profile of microRNAs in head and neck squamous cell carcinomas (HNSCC), we found that the expression level of miR-124 was 4.59-fold lower in tumors than in...